News

Understanding UnitedHealth Group's Options Trading Insights

Understanding UnitedHealth Group's Options Trading Insights

Market Sentiment Surrounding UnitedHealth Group

Insightful analysis reveals that large investors, often referred to as "whales," are showing a considerably bearish outlook on UnitedHealth Group. This shift in sentiment is largely reflected in their trading patterns.

Investor Actions: Options Trading Overview

A recent examination of trading activity for UnitedHealth Group (NYSE: UNH) identified a total of 74 distinct trades. The breakdown of these trades shows that 35% of investors entered trades with bullish expectations while 47% leaned towards pessimism.

Trade Specifics and Financials

Within these unique trades, there were 18 put options, amounting to $2,406,409, contrasted with 56 call options totaling $3,047,647. This suggests a cautious appetite within the investor community.

Predicted Price Range for UnitedHealth Group

By analyzing the volume and open interest related to these contracts, it’s evident that major players forecast a price range for UnitedHealth Group between $180.0 and $600.0 over the recent quarter. This wide range highlights the varying opinions on the company's potential future performance.

Volume & Open Interest Analysis

Understanding the volume and open interest can significantly enhance an investor's strategy when trading options. This information helps monitor liquidity and reveals investor interest for UnitedHealth Group's options at specific strike prices.

30-Day Call and Put Volume Summary

In the last month, data shows a considerable fluctuation in both call and put volumes within the defined strike price range, further emphasizing the ongoing interest from larger investors.

Highlights of Major Options Trades

Among the notable options trades undertaken, several major transactions have been observed, showcasing the behavior of substantial players in this market.

Overview of Significant Options Activities:

Here are some of the largest options trades observed:

  • PUT - Trade Date: 01/16/26: $19.9 strike with total trade $1.2M - bullish sentiment.
  • CALL - Trade Date: 01/16/26: $42.39 strike with total trade $254.3K - bearish sentiment.
  • CALL - Trade Date: 01/16/26: $31.44 strike with total trade $188.6K - bullish sentiment.
  • PUT - Trade Date: 03/20/26: $15.85 strike with total trade $158.5K - bullish sentiment.
  • CALL - Trade Date: 12/17/27: $131.5 strike with total trade $131.5K - bullish sentiment.

About UnitedHealth Group

UnitedHealth Group stands as one of the world's largest private health insurers, providing medical coverage to approximately 51 million members worldwide. This includes about one million members outside the United States. The company has established a dominant position in employer-sponsored, self-directed, and government-supported insurance plans.

Current Stock Performance of UnitedHealth Group

  • The price of UNH currently stands at $343.24, with a trading volume of 3,507,832, reflecting a slight decrease of -0.24%.
  • The stock's RSI indicates it may be nearing an overbought condition.
  • Investors can anticipate the next earnings report in about 29 days.

Analyst Predictions and Ratings

In recent evaluations, four analysts have engaged with UnitedHealth Group, providing an average target price of $372.75. This reflects a positive outlook for the stock moving forward:

  • Barclays holds an Overweight rating with a target of $352.
  • Morgan Stanley maintains an Overweight rating with a projected price of $395.
  • Bernstein supports an Outperform rating with a target of $379.
  • Truist Securities continues to endorse a Buy rating, setting a target of $365.

Engaging in Options Trading

Options trading carries inherent risks but also offers significant opportunities. Savvy traders manage these risks through continuous education, adaptive strategies, and robust monitoring of market signals.

Frequently Asked Questions

What is the current trading sentiment for UnitedHealth Group?

Currently, there is a bearish sentiment among institutional investors based on recent options trading data.

How many trades were identified in the latest analysis of UnitedHealth Group?

The analysis detected a total of 74 individual trades.

What financials are associated with UnitedHealth Group's options trading?

Within the recent trades, 18 puts were traded amounting to $2,406,409, while 56 calls totaled $3,047,647.

What is the analytical prediction for UnitedHealth Group's stock price?

Market predictions indicate a potential price range between $180.0 and $600.0.

What are analysts forecasting for UnitedHealth Group's future performance?

Analysts propose an average target price of $372.75 with various firms maintaining Overweight and Buy ratings.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Updated Category News Views 3

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

Continue Reading
Surfing Dogs Ride Waves, Support Orphan Pets

Updated Category News Views 3

Waves, Paws, and Passion Who would've thought that dogs catching waves could also catch hearts and wallets? Well, that's exactly what's happening today at Del Mar Dog Beach with the 21st Annual Surf Dog Surf-A-Thon revving up the excitement. It's a sun-soaked day in Rancho Santa Fe, California, right in the thick of things at the longest-running dog surf competition. For...

Continue Reading
GORGIE Unleashes Berry Burst: Target's New Drink Star

Updated Category News Views 5

GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...

Continue Reading
PwC US and India Unite for Global Consultancy Powerhouse

Updated Category News Views 6

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...

Continue Reading
PANDAG G1 Debuts: Revolutionizing Lawn Care Efficiency

Updated Category News Views 4

The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...

Continue Reading
Ris-Rez May Set New Standard in Relapsed SCLC

Updated Category News Views 6

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...

Continue Reading
Tam-Peli Steps Up in SCLC Battle: Trial Insights

Updated Category News Views 5

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...

Continue Reading
UWM Faces Class Action Deadline: Key Insights for Investors

Updated Category News Views 2

The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...

Continue Reading
Trial Disappointment: No Significant Gains in NSCLC

Updated Category News Views 7

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

Continue Reading
MRI Surveillance Gains Ground in Lung Cancer Care

Updated Category News Views 6

Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....

Continue Reading

Top 5 Most Recently Viewed Articles

Promising Interim Findings from Medicus Pharma's BCC Study

Updated Category News Views 164

Positive Interim Analysis from Medicus Pharma Ltd Medicus Pharma Ltd. (NASDAQ: MDCX) has recently shared exciting interim results from its SKNJCT-003 Phase 2 clinical study, which focuses on a non-invasive approach to treat basal cell carcinoma (BCC) of the skin. This news marks a significant milestone as the company aims to revolutionize the treatment options available...

Continue Reading
DroneShield's Immediate Response Kit Wins Platinum Award for Innovation

Updated Category News Views 161

DroneShield's Immediate Response Kit Gains Recognition for Innovation DroneShield has recently been awarded the prestigious Platinum Award for Innovation by Military and Aerospace Electronics, showcasing its Immediate Response Kit (IRK) as a cornerstone in drone detection and defeat technology. This award is a testament to the exceptional capabilities of the IRK, which...

Continue Reading
Jefferies Holds ABB Rating; Analysts Assess Mixed Results

Updated Category News Views 65

Jefferies Maintains Hold Rating on ABB Stock Jefferies recently continued its Hold rating for ABB Ltd (NYSE: ABB) and set a price target of CHF50.00, following the company's third-quarter performance report. The report showcased a mixed array of results, with certain metrics outperforming expectations while others showed disappointing trends. During the third quarter, ABB...

Continue Reading
Surgical Clips Market Projected to Reach $1.8 Billion Soon

Updated Category News Views 211

Overview of the Surgical Clips Market Recent analysis of the surgical clips market reveals an impressive valuation of USD 655.9 million in 2023, with projections indicating a potential growth to USD 1.8 billion by 2032. This remarkable increase is attributed to a compound annual growth rate (CAGR) of 11.9% from 2024. Understanding Surgical Clips and Their Importance...

Continue Reading
Public Disclosure of Opening Position by Keywords Studios Plc

Updated Category News Views 74

Public Opening Position Disclosure for Keywords Studios Plc This document provides important information about a public opening position disclosure related to Keywords Studios Plc. It includes details about individuals or entities holding 1% or more of relevant securities. This disclosure is made in accordance with Rule 8.3 of the Takeover Code, which ensures that all...

Continue Reading